Cancer News and Research

Latest Cancer News and Research

Several DNA sequences linked to impaired pulmonary function, uncovers new study

A new study involving data from more than 20,000 individuals has uncovered several DNA sequences linked to impaired pulmonary function. The research, an analysis that combined the results of several smaller studies, provides insight into the mechanisms involved in reaching full lung capacity.

14 Dec 2009

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

Interim results from a European clinical trial, RESTORE 2, demonstrate that cell-enriched breast reconstruction achieved a high rate of patient and physician satisfaction and improvements in overall breast deformity in lumpectomy patients.

14 Dec 2009

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

A new study finds many breast cancer patients - particularly African American women - do not receive recommended radiation treatments after undergoing a lumpectomy.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Algeta ASA, the cancer therapeutics company, announces that the first clinical center in the US, the Tulane Cancer Center, New Orleans, has started randomizing patients in the phase III clinical study of Alpharadin in men with castration-resistant (also known as hormone-refractory) prostate cancer (CRPC) that has metastasized to the skeleton.

14 Dec 2009

Combination therapy improves overall survival in women with advanced breast cancer

In a clinical study, women with an aggressive form of breast cancer experienced a median survival of 14 months when treated with an investigational combination of TYKERB® (lapatinib) plus HERCEPTIN® (trastuzumab). The results of the Phase III study in HER2-positive metastatic breast cancer were presented during the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium, held in San Antonio, Texas (Dec. 9 - 13).

14 Dec 2009

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Black women with hormone receptor (HR)-positive breast cancer had worse disease-free and overall survival, according to data presented at the CTRC-AACR Annual San Antonio Breast Cancer Symposium, held Dec. 9-13, 2009.

14 Dec 2009

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen’s lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.

14 Dec 2009

Concord Medical Services Holdings announces initial public offering of 12,000,000 American Depositary Shares

Concord Medical Services Holdings Limited ("CMS" or "the Company"), operator of the largest network of radiotherapy and diagnostic imaging centers in China in terms of revenues and the total number of centers in operation in 2008, announced today that its initial public offering of 12,000,000 American Depositary Shares ("ADSs"), each representing three ordinary shares of the Company, was priced at $11.00 per ADS.

14 Dec 2009

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Using Herceptin with chemotherapy, instead of after, clearly improves treatment of women with HER2+ breast cancer, and should be the new standard of care, says a Mayo Clinic researcher who led what is regarded to be a key clinical trial determining the best use of Herceptin.

14 Dec 2009

Genentech announces positive results from Phase II study of T-DM1

Genentech, Inc., a wholly owned member of the Roche Group, today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment.

14 Dec 2009

Case Western Reserve University grants option to startup Thermalin Diabetes

Case Western Reserve University has granted an 18-month, exclusive option to startup Thermalin Diabetes Inc. regarding a portfolio of insulin analogs. The company must reach certain milestones in order to exercise its option to obtain an exclusive license on therapies designed to help patients with diabetes.

14 Dec 2009

Texas researchers identify new detection method for circulating tumor cells

Circulating metastatic breast cancer cells can lose their epithelial receptors, a process that enables them to travel through the bloodstream undetected, according to research from The University of Texas M. D. Anderson Cancer Center.

14 Dec 2009

Findings from three studies using bioTheranostics' breast cancer molecular test reported

bioTheranostics, a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, reported today findings from three studies using the company's breast cancer molecular test.

14 Dec 2009

Herb milk thistle help treat liver inflammation in cancer patients who receive chemotherapy, finds study

A new study finds that the herb milk thistle may help treat liver inflammation in cancer patients who receive chemotherapy. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the study indicates that the herb could allow patients to take potent doses of chemotherapy without damaging their liver.

14 Dec 2009

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

New research being presented this week at the 32nd Annual CTRC-AACR San Antonio Breast Cancer Symposium by an investigator at The Cancer Institute of New Jersey (CINJ) highlights the benefit of a shortened radiation course to patients with the most common type of non-invasive breast cancer.

14 Dec 2009

Data from Phase 3 clinical evaluation of Lymphoseek presented

Neoprobe Corporation, a diversified developer of innovative oncology surgical and diagnostic products, today announced that researchers who participated in the breast cancer arm of a Phase 3 clinical evaluation of Lymphoseek® presented data from their clinical experience at the International San Antonio Breast Cancer Symposium.

14 Dec 2009

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

14 Dec 2009

Scientists discover five genetic variants associated with lung disease

Scientists have discovered five genetic variants that are associated with the health of the human lung. The research by an international consortium of 96 scientists from 63 centres in Europe and Australia sheds new light on the molecular basis of lung diseases.

14 Dec 2009

Cancer News and Research

Latest Cancer News and Research

Several DNA sequences linked to impaired pulmonary function, uncovers new study

Cell-enriched breast reconstruction procedure improves breast deformity in lumpectomy patients

African American women with breast cancer receive no follow-up care after lumpectomy, shows study

Pfizer announces results from studies evaluating neratinib

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Tulane Cancer Center starts randomizing patients in phase III clinical study of Alpharadin

Combination therapy improves overall survival in women with advanced breast cancer

Black women with HR-positive breast cancer have worse disease-free and overall survival, shows data

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Concord Medical Services Holdings announces initial public offering of 12,000,000 American Depositary Shares

Combination of Herceptin and chemotherapy improves treatment for women with HER2+ breast cancer

Genentech announces positive results from Phase II study of T-DM1

Case Western Reserve University grants option to startup Thermalin Diabetes

Texas researchers identify new detection method for circulating tumor cells

Findings from three studies using bioTheranostics' breast cancer molecular test reported

Herb milk thistle help treat liver inflammation in cancer patients who receive chemotherapy, finds study

New research highlights the benefit of shortened radiation course for patients with non-invasive breast cancer

Data from Phase 3 clinical evaluation of Lymphoseek presented

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Scientists discover five genetic variants associated with lung disease

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Cancer News and Research

Latest Cancer News and Research

Cancer Research - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Newsletters you may be interested in